28 août 2016 - FDA announced required class-wide changes to drug labeling to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system depressant drugs called benzodiazepines. Among the changes, the FDA is requiring boxed warnings and Medication Guides.
Ajouté au bande de temps:
Date:
28 août 2016
Maintenaint
~ Il y a 9 ans